| Literature DB >> 33789101 |
Sarah Abou Alaiwi1, Amin H Nassar2, Elio Adib2, Stefan M Groha3, Elie W Akl4, Bradley A McGregor1, Edward D Esplin5, Shan Yang5, Kathryn Hatchell5, Vincent Fusaro5, Sarah Nielsen5, David J Kwiatkowski2, Guru P Sonpavde1, Mark Pomerantz1, Judy E Garber6, Matthew L Freedman7, Huma Q Rana6, Alexander Gusev3, Toni K Choueiri8.
Abstract
Prior studies of the renal cell carcinoma (RCC) germline landscape investigated predominantly patients of European ancestry. We examine the frequency of germline pathogenic and likely pathogenic (P/LP) variants in 1,829 patients with RCC from various ancestries. Overall, P/LP variants are found in 17% of patients, among whom 10.3% harbor one or more clinically actionable variants with potential preventive or therapeutic utility. Patients of African ancestry with RCC harbor significantly more P/LP variants in FH compared to patients of non-African ancestry with RCC and African controls from the Genome Aggregation Database (gnomAD). Patients of non-African ancestry have significantly more P/LP variants in CHEK2 compared to patients of African ancestry with RCC and non-Finnish Europeans controls. Non-Africans with RCC have more actionable variants compared to Africans with RCC. This work helps understand the underlying biological differences in RCC between Africans and non-Africans and paves the way to more comprehensive genomic characterization of underrepresented populations.Entities:
Keywords: Ancestry; DNA damage repair; clinical genetics; germline variants; kidney cancer; renal cell carcinoma
Mesh:
Substances:
Year: 2021 PMID: 33789101 DOI: 10.1016/j.celrep.2021.108926
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423